НАЗНАЧЕНИЕ ГОРМОНАЛЬНОЙ ТЕРАПИИ ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ: ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД НА ОСНОВЕ БИОЛОГИЧЕСКИХ ПОДТИПОВ
Ключевые слова:
рак молочной железы, таргетная и системная химиотерапия, люминальный тип А, люминальный тип В, белок HER2.
Аннотация
Пациенты с гормоночувствительными и амплифицированными подтипами опухоли Her2neu имеют
лучший краткосрочный прогноз, чем пациенты с гормонотрицательными и сверхэкспрессирующими
подтипами Erb-B2. При гормонопозитивном люминальном А подтипе рака молочной железы
гормональная терапия является единственной эффективной системной терапией, которую следует
применять у пациенток, находящихся в хорошей физической форме.
Литература
1.Diab S.G. Tumor characteristics and clinical outcome of elderly women with breast cancer. /Elledge R.M, Clark G.M. //JNatlCancerInst 2000. –V. 92. –P 550–556
2.RudenstamC . Randomized trial comparing axillary clearance versus no axillary clearance inolder patients with breast cancer: first results of International
Breast Cancer Study Group. Trial 10-93. /Zahrieh D. // J ClinOncol 2006. –V.24. –P.337–344
3.Schrag D. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. / Kuntz K, Garber J. // JAMA 2000.-V.283. –P.617–624
4.Christman K. Chemotherapy of metastatic breast cancer in the elderly. / Muss H.B, Case L.D. //ThePiedmontOncologyAssociationexperience. JAMA 2012.-V. 268.-P 57–62
5.Slamon D. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / LeylandJones B, Shak S. NEnglJMed 2001. –V.344.-P. 783–792
6.Dowsett M. Prediction of risk of distant recurrence using the 21-gene recurrence score in nodenegative and node-positive postmenopausal patients
with breast cancer treated with anastrozole or tamoxifen: aTransATAC study. /Cuzick J, Wale C.// JClinOncol 2010.-V.28.-P 1829–1834
7.Semiglazov V.F. Breast cancer. Biology, local and systemic treatment. In Russian/Semiglazov V.V. // SIMK 2014. N.1. P- 298-341
8.Gregor M. Trastuzumab-related cardiotoxicity among older breast cancer patients. /Zhang N, Niu J. //ASCO Meeting Abstract. JClinOncol 2012.-V.30. -P 135
9.Slamon D. Adjuvant Trastuzumab in HER2- Positive Breast Cancer. // Eiermann W, Robert N. // NEnglJMed 2011.-V. 365.-P. 1273–83
10.Partridge A. Adherence and persistence with oral adjuvant chemotherapy in older women with earlystage breast cancer in CALGB 49907: adherence companion study 60104. / Archer L, Kornblith A. // JClinOncol 2010. –V. 28.-P. 2418–2422
11.Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. / Holmes F, O’Shaughnessy J. // JClinOncol 2009. –V. 27. – P 1177–1183
12.Albain K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. /Anderson S, Arriagada R.// Lancet 2012. -V.379.-P 432–444
13.Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. / Holmes F, O’Shaughnessy J. // JClinOncol 2009. –V. 27. – P 1177–1183
14.Wildiers H. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. / Kunkler I, Biganzoli L. // LancetOncol 2007. –V.8.-P.1101–1115
15.Abe O. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. /
Abe R, Enomoto K.// Lancet 2005. –V.365. –P 1687– 1717
16.Sawaki M. Safety of adjuvant trastuzumab for HER - 2- overexpressing elderly breast cancer patients: a multicenter cohort study. / Mukai H, Tokudome N. //
Breast Cancer 2012. –V.19.-P. 253–258
17.Foulkes W. Triple-negativebreastcancer. /Smith I, Reis J.// NEnglJMed 2010.-V.363.-P 1938– 1948
18.Geyer C. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. /Forster J, Lindquist D. //NEnglJMed 2006.-V.355.-P 2733–2743
19.Freyer G. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. /Campone M, Peron J.// ritRevOncolHematol 2011.- V.80.-P 466–473
20.Paik S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. / Tang G, Shak S. // JClinOncol 2006. –V.24.-P 3726–3734
21.Ravdin P. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. / Siminoff L, Davis G. // JClinOncol 2001. –V.19. –P. 980–991
22.Burstein H J. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. / PrestrudA.A, Seidenfeld J.// J Clin.Oncol 2010.-V. 28.-P 3784–3796
23.Muss H. Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. /Berry D, Cirrincione C.// NEnglJMed 2010. –V. 360.-P 2055– 2065
2.RudenstamC . Randomized trial comparing axillary clearance versus no axillary clearance inolder patients with breast cancer: first results of International
Breast Cancer Study Group. Trial 10-93. /Zahrieh D. // J ClinOncol 2006. –V.24. –P.337–344
3.Schrag D. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. / Kuntz K, Garber J. // JAMA 2000.-V.283. –P.617–624
4.Christman K. Chemotherapy of metastatic breast cancer in the elderly. / Muss H.B, Case L.D. //ThePiedmontOncologyAssociationexperience. JAMA 2012.-V. 268.-P 57–62
5.Slamon D. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. / LeylandJones B, Shak S. NEnglJMed 2001. –V.344.-P. 783–792
6.Dowsett M. Prediction of risk of distant recurrence using the 21-gene recurrence score in nodenegative and node-positive postmenopausal patients
with breast cancer treated with anastrozole or tamoxifen: aTransATAC study. /Cuzick J, Wale C.// JClinOncol 2010.-V.28.-P 1829–1834
7.Semiglazov V.F. Breast cancer. Biology, local and systemic treatment. In Russian/Semiglazov V.V. // SIMK 2014. N.1. P- 298-341
8.Gregor M. Trastuzumab-related cardiotoxicity among older breast cancer patients. /Zhang N, Niu J. //ASCO Meeting Abstract. JClinOncol 2012.-V.30. -P 135
9.Slamon D. Adjuvant Trastuzumab in HER2- Positive Breast Cancer. // Eiermann W, Robert N. // NEnglJMed 2011.-V. 365.-P. 1273–83
10.Partridge A. Adherence and persistence with oral adjuvant chemotherapy in older women with earlystage breast cancer in CALGB 49907: adherence companion study 60104. / Archer L, Kornblith A. // JClinOncol 2010. –V. 28.-P. 2418–2422
11.Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. / Holmes F, O’Shaughnessy J. // JClinOncol 2009. –V. 27. – P 1177–1183
12.Albain K. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials. /Anderson S, Arriagada R.// Lancet 2012. -V.379.-P 432–444
13.Jones S. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. / Holmes F, O’Shaughnessy J. // JClinOncol 2009. –V. 27. – P 1177–1183
14.Wildiers H. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. / Kunkler I, Biganzoli L. // LancetOncol 2007. –V.8.-P.1101–1115
15.Abe O. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the randomised trials. /
Abe R, Enomoto K.// Lancet 2005. –V.365. –P 1687– 1717
16.Sawaki M. Safety of adjuvant trastuzumab for HER - 2- overexpressing elderly breast cancer patients: a multicenter cohort study. / Mukai H, Tokudome N. //
Breast Cancer 2012. –V.19.-P. 253–258
17.Foulkes W. Triple-negativebreastcancer. /Smith I, Reis J.// NEnglJMed 2010.-V.363.-P 1938– 1948
18.Geyer C. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. /Forster J, Lindquist D. //NEnglJMed 2006.-V.355.-P 2733–2743
19.Freyer G. Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study. /Campone M, Peron J.// ritRevOncolHematol 2011.- V.80.-P 466–473
20.Paik S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. / Tang G, Shak S. // JClinOncol 2006. –V.24.-P 3726–3734
21.Ravdin P. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. / Siminoff L, Davis G. // JClinOncol 2001. –V.19. –P. 980–991
22.Burstein H J. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. / PrestrudA.A, Seidenfeld J.// J Clin.Oncol 2010.-V. 28.-P 3784–3796
23.Muss H. Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. /Berry D, Cirrincione C.// NEnglJMed 2010. –V. 360.-P 2055– 2065
Опубликован
2022-02-17
Как цитировать
Алимходжаева, Л.Т, и Р.Р. Юлдашев. 2022. «НАЗНАЧЕНИЕ ГОРМОНАЛЬНОЙ ТЕРАПИИ ПРИ РАКЕ МОЛОЧНОЙ ЖЕЛЕЗЫ: ПЕРСОНАЛИЗИРОВАННЫЙ ПОДХОД НА ОСНОВЕ БИОЛОГИЧЕСКИХ ПОДТИПОВ». EurasianUnionScientists, февраль, 29-32. https://bio-med.euroasia-science.ru/index.php/Euroasia/article/view/810.
Выпуск
Раздел
Статьи
CC BY-ND
Эта лицензия позволяет свободно распространять произведение, как на коммерческой, так некоммерческой основе, при этом работа должна оставаться неизменной и обязательно должно указываться авторство.
